AncestryDNA
As founder, it was Ken’s vision that brought AncestryDNA into existence. Drawing on his Ph.D. in genetics, he laid the groundwork for what would become a revolutionary product—one that, for the first time, could reveal an individual’s ethnicity with remarkable accuracy and identify distant cousins through shared ancestors dating back to the 1800s. Leveraging his legal background, he skillfully navigated complex regulatory challenges, addressed profound ethical dilemmas such as false paternity, and protected consumer privacy. By weaving this scientific and legal expertise together with sharp business acumen, he created the most popular genetic test ever developed.
Hemophilia Gene Therapy
Ken served as CEO of Avigen, the company that initially developed the groundbreaking gene therapy product that would become Beqvez™. The treatment was ultimately licensed to Pfizer, which advanced it through global regulatory approvals and now markets it under the Beqvez™ brand name. Designed for adults with hemophilia B, the therapy delivers a functional copy of the Factor IX gene to the liver, enabling the patient’s own cells to produce the missing clotting factor. This innovative, one-time gene therapy represents a functional cure for patients born with this life-threatening genetic disease.
Helio Liver
Ken was the CEO and primary inventor behind the multiomic HelioLiver™ platform—a breakthrough, blood-based test for the early detection of hepatocellular carcinoma (HCC). Designed for high-risk patients, the diagnostic combines protein biomarkers, cell-free DNA methylation analysis, and machine learning to identify liver cancer at earlier, more treatable stages. Currently under FDA review, the test has the potential to transform clinical practice by enabling accurate detection through a simple blood sample—representing a significant advancement in the global effort to reduce liver cancer mortality.
Nectar Allergy
Ken was the founder and CEO of Nectar Allergy, a company that reinvented allergy care through innovation, accessibility, and technology. Nectar introduced a groundbreaking model of treatment by offering at-home immunotherapy drops instead of traditional allergy shots, combining clinical efficacy with virtual care and a seamless digital experience. The company vertically integrated its operations by establishing a 503A compounding pharmacy licensed in 49 states, enabling personalized treatment at scale. This comprehensive model not only dramatically expanded patient access but also powered a new generation of allergy clinics designed for exceptional clinical quality and enhanced operational profitability.